Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3532226 Effects on Hypoglycemia in T1D
NCT05887999Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2023
- Primary completion
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing LY3532226 Sequence with Placebo Sequence (2 arms). Primary endpoint: Area under the concentration versus time curve from time 60 to 120 minutes of plasma glucagon. Started Jun 2023; status: completed.
02
Drugs
macupatide
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT05887999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05887999.